2-苯甲酰基-1-苯并呋喃-5-甲醛 | 120973-72-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-苯甲酰基-1-苯并呋喃-5-甲醛
• 英文名称: 2-benzoylbenzofuran-5-carbaldehyde
• 英文别名: 2-benzoyl-5-formylbenzofuran；2-benzoyl-1-benzofuran-5-carbaldehyde
• CAS: 120973-72-0
• 化学式: C₁₆H₁₀O₃
• 分子量: 250.254
• InChiKey: CLAPHTYIBWGUCN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  47.3
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2932999099
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2-苯甲酰基-1-苯并呋喃-5-甲醛 在 盐酸 、 sodium hydroxide 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 三乙胺 、 三氟乙酸 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 3-(2-benzoylbenzofuran-5-yl)-N-hydroxyacrylamide
  参考文献：
  名称：

  2-Aroylindoles and 2-Aroylbenzofurans with N-Hydroxyacrylamide Substructures as a Novel Series of Rationally Designed Histone Deacetylase Inhibitors

  摘要：

  Histone deacetylase (HDAC) inhibitors are considered to be drugs for targeted cancer therapy and second-generation HDIs are currently being tested in clinical trials. Here, we report on the synthesis and biological evaluation of a novel HDAC inhibitor scaffold with the hydroxamate Zn2+ complexing headgroup, selected from the 2-aroylindol motif. Inhibition of nuclear extract HDAC and recombinant HDAC I as well as induction of histone H3K(9+14) hyperacetylation mediated by E-N-hydroxy-(2-aroylindole)acrylamides or E-Nhydroxy-(2-aroylbenzofuran)acrylamides were studied. Moreover, the cytotoxic activity, the effects on the cell cycle, and historic H3S(10) phosphorylation of selected compounds were determined. By use of a panel of 24 different human tumor cell lines, mean IC50 values of the most potent analogues 6c and 7b were 0.75 and 0.65 mu M, respectively. The novel compounds were shown to be no substrates of the P-glycoprotein drug transporter. Comparable to N-1-hydroxy-N-8-phenyloctanediamide "2 (SAHA)", cells in the S phase of the cell cycle are depleted, with partial arrest in G1 and G2/M and finally induction of massive apoptosis.

  DOI：

  10.1021/jm0703136
• 作为产物：
  描述：

  甲酮,(5-甲基-2-苯并呋喃基)苯基- 在 N-溴代丁二酰亚胺(NBS) 、 草酰氯 、 偶氮二异丁腈 、 sodium carbonate 、 二甲基亚砜 、 三乙胺 作用下， 以 四氯化碳 、 二氯甲烷 、 氯仿 、 水 、 丙酮 为溶剂， 反应 27.5h， 生成 2-苯甲酰基-1-苯并呋喃-5-甲醛
  参考文献：
  名称：

  Synthetic Approaches to Benzofuran Containing Insulin Sensitivity Enhancer Compounds for Treatment of Type II Diabetes

  摘要：

  DOI：

  10.3987/com-97-7820

文献信息

• Thiazolidinedione derivatives
  申请人：BEECHAM GROUP PLC

  公开号：EP0299620A1

  公开（公告）日：1989-01-18

  A compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein: A° represents nitrogen or a moiety wherein R1 represents hydrogen, alkyl or a substituted or unsubstituted aryl group; R2 represents a moiety R3-Y-Z- wherein R3 represents substituted or unsubstituted phenyl, substituted or unsubstituted pyridyl or a substituted or unsubstituted oxazolyl group, and Y represents -(CH2)n. wherein n represents zero or any integer in the range of 1 to 6 and Z represents -CH2-,-CH(OH)- or -CO-; Ra and Rb each represent hydrogen or Ra and Rb together represent a bond; A represents a residue of a benzene ring, the carbon atoms of the residue having in total up to four substituents; and X represents 0 or S; a process for preparing such a compound, a pharmaceutical composition containing such a compound and the use of the compound and composition in medicine.

  一种化合物的化学式（I）： 或其药学上可接受的盐，其中：A°代表氮或一个基团 其中 R1代表氢、烷基或一个取代或未取代的芳基； R2代表一个基团R3-Y-Z-，其中R3代表取代或未取代的苯基、取代或未取代的吡啶基或一个取代或未取代的噁唑基，Y代表-(CH2)n，其中n代表零或在1到6范围内的任意整数，Z代表-CH2-，-CH(OH)-或-CO-； Ra和Rb各自代表氢或Ra和Rb一起代表一个键； A代表苯环的残基，残基的碳原子总共最多有四个取代基； X代表0或S；一种制备这种化合物的方法，含有这种化合物的药物组合物以及在医学中使用该化合物和组合物。
• Synthesis and Insight into the Structure–Activity Relationships of Chalcones as Antimalarial Agents
  作者：Narender Tadigoppula、Venkateswarlu Korthikunta、Shweta Gupta、Papireddy Kancharla、Tanvir Khaliq、Awakash Soni、Rajeev Kumar Srivastava、Kumkum Srivastava、Sunil Kumar Puri、Kanumuri Siva Rama Raju、Wahajuddin、Puran Singh Sijwali、Vikash Kumar、Imran Siddiqi Mohammad

  DOI：10.1021/jm300588j

  日期：2013.1.10

  licorice, is the most promising antimalarial compound reported so far. In continuation of our drug discovery program, we isolated two similar chalcones, medicagenin (II) and munchiwarin (III), from Crotalaria medicagenia, which exhibited antimalarial activity against Plasmodium falciparum. A library of 88 chalcones were synthesized and evaluated for their in vitro antimalarial activity. Among these, 67,

  从中国甘草的根中分离得到的Licochalcone A（I）是迄今为止报道的最有前途的抗疟化合物。在继续我们的药物发现计划时，我们从猪屎豆属中分离了两个类似的查耳酮，medicageninin（II）和munchiwarin（III），它们对恶性疟原虫具有抗疟活性。合成了88个查耳酮的文库，并对其体外抗疟活性进行了评估。在这些中，67，68，74，77，和78显示出在体外对抗疟疾活性良好恶性疟原虫具有低细胞毒性的3D7和K1菌株。这些查耳酮还显示出寄生虫约瑟氏疟原虫（N-67株）感染的瑞士小鼠的寄生虫病减少和存活时间增加。药代动力学研究表明，不良的ADME特性导致口服生物利用度低。分子对接研究揭示了这些抑制剂在falcipain-2（FP-2）酶的活性位点的结合方向。化合物67，68，和78显示出对主要血红蛋白降解半胱氨酸适度抑制活性蛋白酶FP-2。
• [EN] ANABASEINE DERIVATIVES USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES<br/>[FR] DERIVES D'ANABASEINE UTILES POUR LE TRAITEMENT DE MALADIES NEURODEGENERATIVES
  申请人：MEMORY PHARM CORP

  公开号：WO2004019943A1

  公开（公告）日：2004-03-11

  The compounds of the present invention are of formula (I): wherein A, R3, R4 is as defined herein, are useful as ligands for nicotinic receptors.

  本发明的化合物的化学式为（I）：其中A、R3、R4如本文所定义，可用作尼古丁受体的配体。
• Heterocyclic compounds, methods for the preparation thereof, and uses thereof
  申请人：MEMORY PHARMACEUTICALS CORP.

  公开号：US20040229868A1

  公开（公告）日：2004-11-18

  The compounds of the present invention are of formula I: 1 wherein A, R 3 , R 4 is as defined herein, are useful as ligands for nicotinic receptors.

  本发明的化合物的化学式为I:1，其中A、R3、R4如本文所定义，可用作尼古丁受体的配体。
• Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
  申请人：Pulici Maurizio

  公开号：US20050020583A1

  公开（公告）日：2005-01-27

  Compounds which are amino-phthalazinone derivatives according to formula 1 and pharmaceutically acceptable salts thereof, together with pharmaceutical compositions comprising them are disclosed; these compounds or compostions are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, autoimmune diseases and neurodegenerative disorders.

  公开了按照式1的氨基-菲嗪酮衍生物和其药学上可接受的盐，以及包含它们的制药组合物；这些化合物或组合物在治疗由于和/或与改变的蛋白激酶活性有关的疾病中是有用的，如癌症，细胞增殖性疾病，阿尔茨海默病，病毒感染，自身免疫性疾病和神经退行性疾病。